Gemeinschaftspraxis für Hämatologie und Onkologie
- Address
- Otto-von-Guericke-Straße 110, 39104 Magdeburg, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
This hematology and oncology group practice specializes in advanced cancer treatment and clinical research, with particular expertise in gastrointestinal malignancies. The center actively participates in innovative therapeutic trials that combine novel targeted agents with established chemotherapy regimens to improve outcomes for patients with advanced cancers.
- Advanced colorectal cancer treatment strategies
- Combination therapy trials with targeted biologics and chemotherapy
- Second-line cancer treatment protocols
The practice demonstrates commitment to precision oncology through participation in randomized phase 2 studies evaluating FOLFIRI/FOLFOX chemotherapy regimens combined with bevacizumab and investigational agents. Their research portfolio emphasizes improving progression-free survival outcomes in patients with advanced gastrointestinal cancers through innovative combination approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis für Hämatologie und Onkologie
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase II Multicenter Study of Acalabrutinib in Elderly or Frail Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia | University Of Cologne | Phase II | Not Recruiting | May 2021 | May 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 1 | Unknown | 2021-05-20 | 2021-05-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.